The Product Quality Review: From Annual Obligation to Process Knowledge

The Product Quality Review is often written once a year from a template and filed. EU GMP Chapter 1 intends something more useful: a periodic check on whether the process and its specifications remain appropriate, and a trigger for improvement.

What Chapter 1 asks for

Chapter 1 requires regular periodic or rolling quality reviews of all authorised medicinal products, including export-only products, with the aim of verifying the consistency of the existing process and the appropriateness of current specifications. Reviews are normally conducted annually and documented, and may be grouped by product type, such as solid dosage forms, where scientifically justified. The marketing authorisation holder and the manufacturer are both involved where they are different parties, and the technical agreement should define who does what.

What should be in the review

  • Starting and packaging materials, particularly from new sources, and supply chain traceability for active substances.
  • Critical in-process controls and finished product results.
  • All batches that failed specification, with investigations.
  • Deviations, their root causes and the effectiveness of CAPA.
  • Changes to processes or analytical methods, and variations submitted, granted or refused.
  • Stability monitoring results and any adverse trends.
  • Returns, complaints and recalls.
  • Qualification status of equipment and utilities, and post-marketing commitments.

From compilation to conclusion

Chapter 1 expects the review to be evaluated and a conclusion drawn, including whether corrective or preventive action or revalidation is appropriate. The weak PQR is a compilation of tables with the sentence “no trends observed” at the end. A stronger one applies statistical trending, such as control charts for assay, dissolution or fill weight, and asks whether capability is changing, even while every batch is within specification.

Linking the review to the wider system

Management should receive the results and decide on actions. Findings should flow into change control, the risk assessments under ICH Q9(R1) and the management review described in ICH Q10. For contract manufacturing, the review requires data from several parties on time, so the quality agreement should set data deadlines, not only the duty to produce the report. For veterinary medicines, EU veterinary GMP contains an equivalent expectation, and complaints and pharmacovigilance signals belong in the evaluation.

Common mistakes

Frequent problems include reviews that arrive months late, data from contract sites that is incomplete, limits that have not been revisited for years and conclusions that do not result in any action. A short, documented action plan with owners and dates, reviewed at the next management review, closes the loop and is easy to show an inspector.

How PQRA helps

PQRA can help redesign the review process, set up trending that is meaningful for your products, align responsibilities between marketing authorisation holders and contract manufacturers, and check the conclusions against regulatory commitments in the dossier.

Contact PQRA to discuss improving your product quality review process.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *